Eli Lilly moves to curb black-market sales of retatrutide amid rising illicit demand

Eli Lilly announced steps to address the growing black‑market trade of its obesity/diabetes drug retatrutide, which has seen increasing illicit use.

The company is working with law‑enforcement and supply‑chain partners to identify and shut down unauthorized distributors, aiming to protect patients and preserve pricing integrity.

The move comes as other biotech news emerges, including Khartis Therapeutics raising $95 million for oral immunology programs and safety concerns raised for a Neurocrine drug, but the focus remains on Lilly’s effort to curb the illegal market.